Figure 2.

Promising Personalized iPSC-CM Model for Assessing Cardiotoxicity

Patient-derived somatic cells can be reprogrammed to induced pluripotent stem (iPS) cells by using Yamanaka’s cocktail of transcription factors and then robustly differentiated into cardiomyocytes (iPSC-CMs) while retaining the individual’s genetic composition. Drug effects on these cells can be assayed through an expanding repertoire of phenotypic outputs to: 1) address whether there are any CV toxicities; 2) if so, their underlying mechanism; and 3) evaluate for potential cardioprotective agents. CV = cardiovascular.